Hello and welcome to the Unicure NVEGM twenty twenty. Please note that today's meeting is being recorded. Also, may be forward looking statements made during this meeting, which are subject to a Safe Harbor as provided in the slide presentation. It is now my pleasure to turn today's meeting over to Philip Astley Spark, Chairman of the Board of Directors of Unicur. Mr.
Astley Spark, the floor is yours.
Thank you. Good afternoon, Europe, and good morning in The United States. My name is Philip Asley, Spark Chairman of Unicure's Board of Directors, and it is my pleasure to welcome you to this twenty twenty Extraordinary General Meeting of Shareholders of Unicure NV. The sole agenda item for today's meeting is the appointment of Robert Good, our former Chief Medical Officer and Executive Director and a Non Executive Director of Unicure NV. Due to the COVID-nineteen pandemic, it is not possible to conduct this meeting in person in Amsterdam as we usually do.
Therefore, we are holding this EGM virtually as we did with our Annual General Meeting with Shareholders held last June. In accordance with legal requirements as ruled in Dutch emergency legislation, we announced this meeting on Tuesday, 10/27/2020 in the Dutch newspaper and on our Unicure website. On our website, we have provided additional information regarding the conduct of the meeting. The key difference for this meeting compared to our prior meeting is that shareholders are not attending in person and will not be able to vote their shares in real time. Instead, all voting was conducted in advance of the meeting.
I would also like to point out that those who returned the proxy solicited by Unicure have authorized the persons named in the proxy, Matthew Kapusta, David Severney and me to vote on the proposition coming before the meeting. Please note that unlike the format of our prior in person meetings, if you have previously submitted a proxy, including over the Internet or by phone, your vote at this virtual meeting cannot be revoked. In the proxy materials, shareholders have been invited to submit questions regarding agenda items in advance of the meeting and no later than 11:59AM Central European Time on 11/30/2020. Dave, can I assume that there are no questions received?
That's correct. No questions have been received.
Okay, very good. So before proceeding to the business of the meeting, I would like to take a moment to introduce those who are participating. On behalf of the Unicure Board, we have Matthew Kapusta, our Chief Executive Officer and Executive Member of the Board of Unicure Jack Kaye, Chair of our Audit Committee David Meek, a Non Executive Member of the Board Leonard Post, a Non Executive Member of the Board Paul Sotropoulos, a Non Executive Member of the Board and Jeremy Springhorn, the Chair of our Non and Governance Committee. We also have several representatives of the company attending today: Robert Good, our former Chief Medical Officer, who is standing for appointment to the Board at this meeting David Severini, our Chief Legal Officer, who will serve as Secretary of this meeting Matthijs von Blochland, Legal Counsel to Unicure Chiara Rosso, our Associate Director of Investor Relations and Communications and Bart Crack, representing the Dutch notary firm of Holdinger Matheson Crack in Amsterdam, which has been retained by Unicure to assist with the voting and administration of today's meeting. This meeting is held pursuant to the notice given to each shareholder of record at the close of business on 11/03/2020.
Notice of the meeting was posted on our website, www.unicure.com, on or about 10/27/2020, and was filed with the the Securities and Exchange Commission on 11/02/2020. To be counted at this AGM, the ordinary shares were required to be voted in advance of this meeting by the deadline of 11:59 p. M. Central European Time on 11/30/2020. There are 29,308,190 ordinary shares represented by proxy at this meeting, representing approximately 66 of the outstanding voting ordinary shares of Unicure.
This represents a quorum as required by the company's Articles of Association. The resolution to appoint Doctor. Gertz shall be adopted unless the shareholder's resolve to overrule the binding nomination of the nonexecutive directors by at least a two third majority of the votes cast at the EGM, where such votes against represent at least half of the issued share capital of Unicure. On behalf of the Board of Directors of Unicure, I'd like to express my appreciation to all shareholders who return their proxies and especially to all shareholders who have taken the time to join us today. At this time, we will begin the discussion of the second agenda item and the only voting proposal.
The proposal to be acted upon by the shareholders is the appointment of Doctor. Robert Gertz as a nonexecutive director of the Board. Based on the unanimous nomination of the Nominating and Corporate Governance Committee, the Board has unanimously resolved to appoint Doctor. Gertz as a Non Executive Director of the Board effective as of the close of this meeting for a term ending at the end of the Annual General Meeting of Shareholders of the company in 2022. This item is more fully described in our notice of extraordinary general meeting and proxy statement, copies of which have been made available to all shareholders and are available at this meeting via the company's website and the Computershare platform that we're using for this meeting.
Doctor. Gott served as Unicore's Chief Medical Officer from August 2018 until October 2020. Doctor. Foote originally served as a Non Executive Director of Unicure from June 2018 through August 2018. And then after accepting the position of Chief Medical Officer of Unicure, he was reappointed served as an Executive Director of Unicure from October 2018 through October 2020.
Under Dutch law, following his resignation as Chief Medical Officer, Doctor. Gott is not able to continue to serve on the Board as an Executive Director. And to continue to serve on the Board, he must be reappointed as a nonexecutive director. As Chief Medical Officer of UniCure, Doctor. Gott led the clinical development, clinical operations, medical affairs and patient advocacy teams that successfully initiated and executed our HOPE B pivotal trial of tranygene desapamovac for hemophilia B and our Phase III clinical trial of AMT-one hundred thirty for the treatment of Huntington's disease.
Doctor. Gott has more than twenty two years of experience in the pharmaceutical and biopharmaceutical industry, leading clinical and medical activities in gene therapy, rare disorders, hematology, endocrinology and other therapeutic areas. Doctor. Gott is the beneficial owner of ordinary shares and options to purchase ordinary shares of Unicure. Details of his biography and equity holdings are listed in our proxy statement.
The Board believes that Doctor. Gott is qualified to serve on the Board of Directors as a non executive director due to his extensive experience in the biotechnology industry. The Board unanimously recommends a vote for the appointment of Doctor. Gurk as a Non Executive Director for a term ending at the company's Annual General Meeting in 2022. The Board's statement in support of this proposal appears in Unicore's proxy statement beginning on Page six.
We will now announce the voting instructions received for this proposal. Because all voting was conducted prior to the meeting, these instructions represent the final results of this proposal, but is subject to verification and certification by Mr. Crack, who is serving as notary for this meeting. I'll now turn it over to the Secretary of the meeting, Dave Suverne.
In accordance with all the received voting instructions and pending certification of vote, there are 29,140,381 votes for, 153,755 votes against, 14,054 votes abstained and no non cast or uncast votes for the proposal. Therefore, the proposal is adopted.
With that, and on behalf of all of directors of Uniper, I would like to welcome Doctor. Good to the Board. Dave, I assume that we have received no further questions in relation to Lane before this meeting?
Yes, that's correct.
Very good then. Following this meeting, the Secretary will complete the counts of the proxies, including examination of all proxies for validity and report the final results of the vote. The meeting is adjourned. I would like to thank you all for attending. I'll now turn the meeting back to the operator.
This concludes the meeting. You may now disconnect.